Board summary
Key figures
49,793
Registered population
62.8% aged 18–64
11.9%
Aged 65+
ICB 14.9% · England 17.9%
36.1%
Ethnic minority (non-White)
11.3% Asian · England 9.6%
76.5%
In IMD quintile 1
ICB 40.7% · England 21.0%
~25,072
Core20 residents (est.)
Resident basis; registered basis ~40,513 · see page 3
7,048
Hypertension register
+8.80% in 3 yrs · England +5.60%
622
SMI register
6.6% of Manchester (LAD)'s
1,388
COPD register
Reviews +12.65% in 3 yrs
Forecast to 2030
8,489
Hypertension patients, 2030
+1,441 on today
88.8%
QRISK ≥20% on statins, 2030
+5.63pp over 3 yrs
3.1%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma review gap alongside high youth prescribing.
With 67.9% of 2,846 asthma patients reviewed, about 910 lack a 12-month review while youth asthma prescribing is 1,832 per 1,000 (England 1,488).
Pre-school booster and MMR2 trail the target.
Age-5 4-in-1 booster coverage is 70.2% (England 80.9%), 24.8 pp below the 95.0% target, while age-5 MMR2 is 76.2% (England 82.8%).
Lipid therapy and COPD reviews exceed England.
Lipid-lowering therapy in QRISK ≥ 20% reaches 76.1% (England 63.6%; ICB 67.0%), and 12-month COPD reviews reach 80.8% (England 76.4%).
Population, age and ethnicity
Children comprise 25.3% of registered patients while non-White residents reach 36.1%
Across 7 practices and 49,793 registered patients, Clayton Beswick & Openshaw PCN is younger than benchmarks: 25.3% (12,594 patients) are aged 0-17 (Manchester 21.4%; ICB 21.8%; England 19.6%), while 11.9% (5,926 patients) are aged 65+ (Manchester 9.6%; ICB 14.9%; England 17.9%). Census usual residents (not registered patients) indicate a 36.1% non-White population, led by Black residents at 16.1% (Manchester 11.9%; ICB 4.7%; England 4.2%) and Asian residents at 11.3% (Manchester 20.9%; ICB 13.6%; England 9.6%).
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Manchester (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Manchester LA) | 2,357 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 80.6% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 53.4% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Manchester LA) | 1,281 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Manchester LA) | 26.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 patients represent 76.5% of registrations, varying by 26.4 pp across practices
The PCN has an average IMD decile of 2.1, compared with 3.0 in Manchester, 4.5 in the ICB, and 5.5 in England. Across the PCN, 76.5% of registered patients are in the Core20 cohort (Manchester 59.8%, ICB 40.7%, England 21.0%). Practice shares range by 26.4 pp, from 66.3% at Lime Square Medical Centre to 92.7% at Five Oaks Family Practice. Practice Core20 estimates total 40,513 registered patients versus 25,072 resident decile 1+2 estimates. Reconciling these denominator bases is necessary before targeting Core20 outreach.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
622
SMI register
1.21% recorded prevalence
348
Learning disability register
0.68% recorded prevalence
8
Care homes, 265 beds
In the PCN catchment
8.7%
Provide unpaid care
Manchester (LAD), Census 2021
Recorded severe mental illness prevalence is 1.2% (622 patients) and learning disability is 0.7% (348 patients), alongside 8 catchment care homes with 265 beds. Separate Manchester borough data show 8.7% unpaid care and 55 rough sleepers, which cannot be extrapolated to practice lists.
Severe mental illness: physical health checks
SMI prevalence is 1.2% (England 1.0%). Over 2023 to 2025, blood pressure check progress (+2.9 pp) trailed England (+4.4 pp), reaching 84.0% (England 83.4%). BMI checks reached 88.2% (England 82.1%). Individual checks do not establish complete physical review completion.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,048
Hypertension register
+8.80%
Register growth, 3 yrs
Manchester (LAD) +4.49% · England +5.60%
+2.78pp
BP control, under 80
≤140/90 · +1.33pp aged 80+
+1,441
More patients by 2030
Forecast 8,489 (16.24%)
Hypertension case-finding and control
Hypertension prevalence is 13.7% (7,048 patients), above Manchester LAD (10.5%) but below the ICB (14.4%) and England (15.2%). The register grew +8.8% over 2023 to 2025 (England +5.6%). Blood pressure checks reached 89.1% (England 90.0%; ICB 90.3%), while control to target was 69.4% (England 70.3%; ICB 71.4%). For patients aged under 80, control reached 66.8% (England 67.8%; ICB 68.6%), while control at age 80+ was 82.4% (England 81.2%). Observation periods are not confirmed. Trailing ICB and England benchmarks for blood pressure control among patients aged under 80 suggests an opportunity to prioritise clinical titration reviews.
Lipids and statins
Lipid therapy in patients with QRISK ≥ 20% reached 76.1%, exceeding Manchester LAD (70.5%), the ICB (67.0%) and England (63.6%), alongside strong coverage in diabetes (80.5% without CVD; 90.4% with CVD). Exceeding national lipid therapy benchmarks across high-risk groups means the PCN should focus on sustaining routine initiation and monitoring.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 94,498 | £1.80 | £1.94 | £1.86 | £170,096 |
| Cardiovascular (all), 2025 | 128,635 | £2.41 | £3.15 | £3.33 | £310,010 |
For lipid-regulating drugs in 2026, the PCN prescribed 94,498 items at £1.80 per item (spend £170,096), below England (£1.86), the ICB (£1.94) and Manchester LAD (£2.21). The PCN spent £5,670 less than at England's unit cost. Lower unit costs than England indicate an opportunity to confirm that lipid-regulating prescribing aligns with clinical appropriateness across target patient cohorts.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+4.86%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.25%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.7% (1,388 patients; England 1.9%), with 80.8% reviewed within 12 months (England 76.4%; +12.7% over 2023 to 2025 vs England +2.8%). Asthma prevalence is 6.0% (2,846 patients; England 6.6%). While 67.9% received an annual review (England 65.7%), about 910 patients remain unreviewed. Furthermore, young-person asthma prescribing is high at 1,832 items per 1,000 aged 5-19 (England 1,488), while second-hand smoke recording trails at 75.8% (England 78.8%). High paediatric prescribing alongside unreviewed patients highlights an operational need to proactively target routine reviews.
Cancer register and children's immunisation
Cancer prevalence is 2.5% (1,269 patients), below England (3.8%). In childhood immunisations, Q1 2025/26 COVER data shows uptake below the 95.0% target across milestones: 6-in-1 at 12 months is 88.9% (England 91.0%), and MMR1 at 24 months is 84.1% (England 88.3%). By age 5, MMR2 reaches 76.2% (11.9 pp below MMR1 at 88.1%) and the 4-in-1 booster reaches 70.2% (England 80.9%).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of cancers with a known stage (6,491 of 11,679) across NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (England 55.3%), below the 75.0% national ambition by 2028 by 19.4 pp. Known stage was recorded for 70.8% of registered cancers (11,679 of 16,492), needing about 2,270 extra early-stage cases to reach 75.0%. PCN cervical screening is 63.8% (England 66.8%), spanning 58.5% at Cornerstone Family Practice and 59.5% at Florence House Medical Practice to 69.4% at Five Oaks Family Practice; breast screening is 60.9% (England 69.9%). System staging data cannot establish PCN performance.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Manchester University NHS Foundation Trust in Jul 2026 (provisional), 72.8% of cancer pathways met the 62-day referral to treatment standard, below the 85.0% standard by 12.2 pp, compared with Northern Care Alliance NHS Foundation Trust at 78.6%, Tameside and Glossop Integrated Care NHS Foundation Trust at 76.8%, the ICB at 75.7%, and England at 71.2%. On the 28-day faster diagnosis standard, Manchester University NHS Foundation Trust reached 80.1% against the 75.0% standard (Tameside and Glossop 82.5%, ICB 79.5%, England 79.3%, Northern Care Alliance 75.2%). Provider waits describe system capacity, not PCN referral quality.
| Pathways within standard (%) | Manchester | Tameside and Glossop Integrated Care | Northern Care Alliance | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.06 | 82.48 | 75.20 | 79.53 | 79.32 |
| 31-day treatment (96%) | 92.54 | 96.25 | 94.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 72.85 | 76.77 | 78.65 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Manchester | Tameside and Glossop Integrated Care | Northern Care Alliance | England |
|---|---|---|---|---|
| MRI | 11.68 | 0.00 | 5.09 | 21.40 |
| CT | 14.66 | 0.18 | 4.10 | 9.92 |
| Echocardiography | 4.91 | 0.00 | 31.48 | 28.48 |
| Colonoscopy | 4.51 | 1.51 | 40.04 | 30.83 |
| Gastroscopy | 29.35 | 5.45 | 36.48 | 29.02 |
| All 15 DM01 tests | 8.98 | 0.80 | 15.71 | 23.14 |
| Community services activity | Manchester residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 96,995 | 573,310 |
| Referrals | 20,270 | 94,470 |
| Patients with a contact | 31,040 | 183,535 |
Community services (residents of Manchester), Jun 2026 (provisional). In Jun 2026 (provisional), community service contacts for Manchester borough residents totalled 96,995, with 42,015 contacts involving adults aged 65+, representing 43.3% of all activity. These figures reflect local authority resident contacts rather than PCN-level or registered-patient service activity, so community caseloads cannot be attributed directly to individual practices.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Dr Khan's Practice | 97 | 82.4 | 86.6% | 74.3% | 86.7% |
| Eastlands | 107 | 73.9 | 74.2% | 80.5% | 76.6% |
| Five Oaks | 127 | 92.7 | 61.2% | 67.8% | 76.6% |
| Drs Hanif & | 79 | 77.0 | 59.3% | 73.5% | 70.7% |
| Cornerstone | 107 | 84.7 | 45.9% | 83.9% | 70.5% |
| Florence House | 93 | 88.9 | 61.5% | 65.7% | 69.4% |
| Lime Square | 100 | 66.3 | 50.6% | 70.6% | 66.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Nine of 25 PCN measures trailed England's three-year trend, led by falling dementia registers
Between 2023 and 2025, 9 of 25 measures trailed England. Dementia prevalence fell 10.8% (England +6.0%), heart failure reviews rose 0.7% (England +8.7%), learning disability prevalence fell 0.5% (England +5.4%), and stroke prevalence fell 2.4% (England +2.3%). Strengths outpaced national growth in COPD reviews (+12.7% vs England +2.8%) and cervical screening (+3.1% vs England -1.0%), alongside smoking cessation support (+4.2 pp vs England +0.1 pp). Trailing register growth could reflect coding changes or list turnover rather than true incidence shifts; clinical record audits would test this.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Heart failure reviews
Learning disability register
Stroke register
Diabetes HbA1c control
COPD reviews
Smoking support (SMI)
Cervical screening
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Manchester (LAD) | Asset | PCN | Manchester (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 8 (265 beds) | n/a | Schools (catchment) | 57 | n/a |
| Children's centres | 6 | 34 | Places of worship | 25 | 289 |
| Libraries | 2 | 16 | Homelessness support (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 11 | 68 | Primary academies | 6 | 50 |
| Special schools | n/a | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review recall
Across 2,846 asthma patients, 67.9% had a review in 12 months (England 65.7%; ICB 66.2%; Manchester 67.0%), leaving about 910 unreviewed. For discussion: practices could run a single-template asthma recall offering after-school slots and pairing inhaler prescribing checks with second-hand smoke recording. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Pre-school booster and MMR2 recall
In Q1 2025/26 (cohort 151), age-5 MMR2 is 76.2% (below the 95.0% target by 18.8 pp; England 82.8%) and 4-in-1 booster is 70.2% (below by 24.8 pp; England 80.9%). Moderate effort to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Telephony and front-door access review
In the Jan-Apr 2026 survey, easy phone contact spans 40.8 pp from 45.9% at Cornerstone Family Practice to 86.6% at Dr Khan's Practice (England 56.9%). Low cost, quick to run.
Evidence base: conditions and pathways with an established England-wide differential for this group: Hypertension and stroke (higher prevalence, younger and more severe stroke); Type 2 diabetes (higher prevalence); Chronic kidney disease and kidney failure (higher progression to dialysis); Sickle cell disease and trait; Maternal and perinatal mortality (markedly higher); Prostate cancer (about double the lifetime risk); and others. Read this population count as the denominator for those pathways, and expect local rates to differ from the all-ethnicity benchmark in that direction.
Policy anchor: Health and Wellbeing Boards must develop neighbourhood health plans for 2027/28 during 2026/27; Core20 defined as the most deprived 20% by IMD.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Diverse resident access review (p2) | Black / African / Caribbean / Black British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI health check workflows (p4) | Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Blood pressure titration recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool immunisation call recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Pre-school booster and MMR2 recall (p12) | MMR dose 2 coverage at age 5 · MMR dose 1 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Telephony and front-door access review (p12) | Black / African / Caribbean / Black British · GPPS easy to contact the practice by phone · GPPS survey response rate | 10YHP, hospital to community | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
